Physician profile
Therese C Prentice
NPI 1962507020
$2,905.61
in general payments reported to CMS, 2019-2025
26 companies · $1,050 in 2025
The $1,050 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $149 · 2022: $436 · 2023: $379 · 2024: $891 · 2025: $1,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,320.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,320.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $603.95 | 2021-2025 | |
| Abbott Laboratories | $375.24 | 2021-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Astrazeneca Pharmaceuticals LP | $305.80 | 2023-2025 | Wainua, Farxiga, Lokelma |
| Pfizer INC. | $267.04 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $223.16 | 2021-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $216.81 | 2022-2025 | Lifevest |
| Cvrx, INC. | $168.56 | 2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $144.94 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.22 | 2022-2025 | Jardiance |
| Atricure, INC. | $69.59 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $64.62 | 2024-2025 | Giapreza |
| E.R. Squibb & Sons, L.L.C. | $59.84 | 2022-2023 | Camzyos |
| Edwards Lifesciences Corporation | $39.98 | 2023-2024 | |
| Lexicon Pharmaceuticals, INC. | $34.69 | 2023 | Inpefa |
| Paladin Technology Solutions | $30.78 | 2024-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventice Services, LLC | $30.13 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $25.93 | 2022 | |
| Kestra Medical Technology Services, INC. | $22.97 | 2023 | Assure Wcd |
| United Therapeutics Corporation | $21.79 | 2024 | Tyvaso |
| Novo Nordisk INC | $20.05 | 2024 | Ozempic, Rybelsus |
| Lantheus Medical Imaging, INC. | $18.96 | 2025 | |
| Watermark Medical, INC. | $18.02 | 2025 | |
| Bridgebio Pharma, INC. | $15.29 | 2025 | Attruby |
| Scpharmaceuticals INC. | $15.24 | 2024 | |
| Hologic Sales and Service, LLC | $14.87 | 2024 | Myosure Tissue Removal Device |
| Medicomp INC | $14.14 | 2024 | Telepatch Cardiac Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Therese Prentice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.